Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

S2Medical

0,01 SEK

0,00 %

Mindre end 1K følgere

S2M

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
0,00 %
-8,47 %
-17,56 %
-50,91 %
+2,86 %
+13,68 %
-95,36 %
-99,40 %
-99,70 %

S2Medical operates in the medical technology sector. The company is focused on research and development of various wound healing products. Various products offered include cellulose-based materials and dressings for the healing of burns and chronic wounds. The products are sold under various brands, mainly at a European level. S2Medical was founded in 2013 and is headquartered in Linköping.

Læs mere
Markedsværdi
10,12 mio. SEK
Aktieomsætning
18,31 t SEK
Omsætning
14,91 mio.
EBIT %
38,83 %
P/E
1,08
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
20.2
2026

Årsrapport '25

5.6
2026

Generalforsamling '26

21.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse20.6.2024, 08.32

S2Medical AB: Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

S2Medical
Selskabsmeddelelse6.11.2023, 15.09

S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market

S2Medical
Selskabsmeddelelse25.8.2023, 13.30

S2Medical AB: INTERIM REPORT APRIL - JUNE 2023

S2Medical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse5.7.2023, 06.45

S2Medical AB (publ) announces final outcome in the company's rights issue

S2Medical
Selskabsmeddelelse4.7.2023, 08.21

S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024

S2Medical
Selskabsmeddelelse3.7.2023, 16.26

S2Medical AB: S2Medical (publ) announces preliminary outcome in the company's rights issue

S2Medical
Selskabsmeddelelse16.6.2023, 11.45

S2Medical AB (publ) publishes a prospectus regarding the rights issue

S2Medical
Selskabsmeddelelse8.6.2023, 15.15

S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia

S2Medical
Selskabsmeddelelse31.5.2023, 17.00

S2Medical AB: Interim Report January - March 2023

S2Medical
Selskabsmeddelelse17.5.2023, 11.33

S2Medical AB (publ) signs a distribution agreement for the Iranian market

S2Medical
Selskabsmeddelelse16.5.2023, 14.45

S2Medical AB: S2Medical wins procurement for wound healing items in the Västra Götaland region

S2Medical
Selskabsmeddelelse10.5.2023, 09.34

S2Medical AB: Postponing of publication of the quarterly report for the period January to March 2023

S2Medical
Selskabsmeddelelse24.4.2023, 15.09

S2Medical AB: Postponement of publication of annual report

S2Medical
Selskabsmeddelelse21.4.2023, 13.37

S2Medical AB: S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million

S2Medical
Selskabsmeddelelse13.4.2023, 09.32

S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million

S2Medical
Selskabsmeddelelse28.3.2023, 14.36

S2Medical AB: S2Medical implements a strategic change to reach profitability faster

S2Medical
Selskabsmeddelelse3.3.2023, 11.39

S2Medical AB: S2Medical wins procurement for wound healing equipment in Region Halland

S2Medical
Selskabsmeddelelse22.2.2023, 14.45

Year-end report January - December 2022 S2Medical AB (publ)

S2Medical
Selskabsmeddelelse16.2.2023, 16.44

S2Medical AB: Postponing of publication of the year-end report

S2Medical
Selskabsmeddelelse2.1.2023, 16.15

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

S2Medical
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.